Abstract
Since the identification of Helicobacter pylori in 1983, the pathogen has become the dominant focus of the investigation of peptic ulceration and gastric carcinoma. During the last 7 years, the efficacy of multiple antimicrobial regimens in curing this infection has been examined. More recently, newer treatment approaches-such as dual therapy and 7-day regimens- have shown a high degree of success and have the potential of improving compliance. Vaccines to prevent acquisition of H pylori, and perhaps clear the organism in infected patients, are under development. Still to be determined are the least expensive, most efficacious, and well-tolerated regimen, and optimal length of treatment.
Original language | English (US) |
---|---|
Pages (from-to) | 682-688 |
Number of pages | 7 |
Journal | Formulary |
Volume | 30 |
Issue number | 11 |
State | Published - 1995 |
ASJC Scopus subject areas
- Pharmacology (medical)